Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug INCA33890 enters human testing for Hard-to-Treat cancers

NCT ID NCT05836324

Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This early-phase study tests a new drug called INCA33890 in about 408 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow their growth. Participants must be 18 or older and have tried or cannot take other available therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 570 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2023

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥18 years old * Histologically or cytologically confirmed advanced or metastatic malignancies as defined in the protocol. * Part 1: Participants must have experienced disease progression after treatment with, be intolerant to, or be ineligible for, or refused available therapies, including anti-PD-(L)1 or anti-CTLA4 therapy if applicable, that are known to confer clinical benefit. Part 2: depending on cohort, participants may have received or not prior treatment for the malignancy under study. * ECOG performance status score of 0 or 1. * Willingness to undergo pre- and on-treatment tumor biopsy (core or excisional). Biopsies are mandatory depending on the cohorts. * Presence of measurable disease according to RECIST v1.1. Exclusion Criteria: * Any known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years. * Not recovered to ≤ Grade 1 or baseline from residual toxicities of prior therapy. * Has active autoimmune disease requiring systemic immunosuppression with corticosteroids. * Brain or CNS metastases untreated or that have progressed. * History of organ transplant, including allogeneic stem cell transplantation. * History of clinically significant or uncontrolled cardiac disease. * Active HBV, active HCV, or HIV positive. * Is on chronic systemic steroids (\> 10 mg/day of prednisone or equivalent). * Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment * Participants that have been initiated on or had modifications in anticoagulation therapies within the last 3 months prior to first dose of treatment. * Significant concurrent, uncontrolled medical condition, eg: * Cardiovascular: Participants with known vasculitis, aneurisms, and other vascular malformations of clinical significance or history of myocarditis. * Gastrointestinal: Any bowel obstruction within 60 days prior to C1D1. * Participants with adequate laboratory values within the protocol defined ranges. Other protocol-defined Inclusion/Exclusion Criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced solid tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced solid tumors Metastatic solid tumors Solid tumors

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    39 sites in 9 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Cambridge University Hospitals Nhs Foundation Trust

    RECRUITING

    Cambridge, CB2 0QQ, United Kingdom

  • Cancer Hospital Chinese Academy of Medical Sciences

    NOT_YET_RECRUITING

    Beijing, 100021, China

  • Cancer and Hematology Centers of Western Michigan-Start Midwest

    RECRUITING

    Grand Rapids, Michigan, 49546, United States

  • Centre Hospitalier Universitaire Vaudois (Chuv)

    RECRUITING

    Lausanne, 01011, Switzerland

  • Centre Leon Berard

    RECRUITING

    Lyon, 69373, France

  • Centro Integral Oncologico Clara Campal

    RECRUITING

    Madrid, 28050, Spain

  • Centro Ricerche Cliniche Di Verona

    RECRUITING

    Verona, 37134, Italy

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Fondazione Irccs Istituto Nazionale Dei Tumori

    RECRUITING

    Milan, 20133, Italy

  • Freeman Hospital Newcastle Upon Tyne Foundation Nhs Trust

    RECRUITING

    Newcastle upon Tyne, NE7 7DN, United Kingdom

  • Fundacion Jimenez Diaz University Hospital

    RECRUITING

    Madrid, 28040, Spain

  • Guys and St Thomas Nhs Foundation Trust

    RECRUITING

    London, SE1 9RT, United Kingdom

  • Hackensack University Medical Center

    RECRUITING

    Hackensack, New Jersey, 07601, United States

  • Herlev Og Gentofte Hospital

    RECRUITING

    Herlev, 02730, Denmark

  • Hospital General Universitario Vall D Hebron

    RECRUITING

    Barcelona, 08035, Spain

  • Hospital Universitario 12 de Octubre

    RECRUITING

    Madrid, 28041, Spain

  • Imperial College Healthcare Nhs Trust - Hammersmith Hospital

    RECRUITING

    London, W12 0HS, United Kingdom

  • Institut Gustave Roussy

    RECRUITING

    Villejuif, 94805, France

  • Irccs Istituto Clinico Humanitas

    RECRUITING

    Rozzano, 20089, Italy

  • Istituto Oncologico Della Svizzera Italiana

    RECRUITING

    Bellinzona, 06500, Switzerland

  • Kansai Medical University Hospital

    RECRUITING

    Hirakata, 573-1191, Japan

  • Kantonsspital St. Gallen

    RECRUITING

    Sankt Gallen, 09007, Switzerland

  • Laura and Isaac Perlmutter Cancer Center

    RECRUITING

    New York, New York, 10016, United States

  • Lifespan Cancer Research Institute

    RECRUITING

    Providence, Rhode Island, 02903, United States

  • National Cancer Center Hospital

    RECRUITING

    Tokyo, 104-0045, Japan

  • Nyu Langone Health - Long Island Hospital

    RECRUITING

    Mineola, New York, 11501, United States

  • Odense University Hospital

    RECRUITING

    Odense C, 05000, Denmark

  • Peking University People'S Hospital

    NOT_YET_RECRUITING

    Beijing, 100044, China

  • Rigshospitalet Uni of Hospital of Copenhagen

    RECRUITING

    Copenhagen, 02100, Denmark

  • South Texas Accelerated Research Therapeutics

    RECRUITING

    San Antonio, Texas, 78229, United States

  • Start Barcelona

    RECRUITING

    Barcelona, 08023, Spain

  • The Angeles Clinic and Research Institute

    RECRUITING

    Los Angeles, California, 90025, United States

  • The Cancer Institute Hospital of Jfcr

    RECRUITING

    Tokyo, 135-0063, Japan

  • The Christie Nhs Foundation Trust Uk

    RECRUITING

    Manchester, M20 4BV, United Kingdom

  • The First Affiliated Hospital, Zhejiang University School of Medicine (Fahzu)

    NOT_YET_RECRUITING

    Hangzhou, 310003, China

  • University of Pennsylvania

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • University of Texas Md Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • Valkyrie Clinical Trials

    RECRUITING

    Los Angeles, California, 90067, United States

  • Vejle Hospital

    RECRUITING

    Vejle, 07100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.